VBI Vaccines, Inc. (VBIV) Gets European Support For Pivotal Phase III Sci-B-Vac Trial
Risks in biotech investment tend to increase as a young company gets closer and closer to its first FDA approval.
Posts Tagged ‘Is VBIV A Good Stock To Buy Right Now?’
$23.6M Investment From 2015’s Top Performing Hedge Fund Makes VBI Vaccines, Inc. (VBIV) Even More Undervalued
One would think that a hepatitis B vaccine with 100% efficacy, negligible safety issues, and mountains of clinical data already supporting it would be valued at a little bit more...
New Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK)
No stock is ever a sure thing, but that doesn’t mean you can’t get asymptotically close to one. Following the announcement by VBI Vaccines, Inc.
